156 related articles for article (PubMed ID: 9099970)
1. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
[TBL] [Abstract][Full Text] [Related]
2. Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.
Andersen TI; Eiken HG; Couch F; Kaada G; Skrede M; Johnsen H; Aloysius TA; Tveit KM; Tranebjaerg L; Dørum A; Møller P; Weber BL; Børresen-Dale AL
Hum Mutat; 1998; 11(2):166-74. PubMed ID: 9482581
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
Andersen TI; Børresen AL
Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre JF; Smith-Sorensen B; Friend SH; Kassell J; Borresen AL; Yan YX; Russo C; Sato J; Barbier N; Miser J
J Clin Oncol; 1994 May; 12(5):925-30. PubMed ID: 8164043
[TBL] [Abstract][Full Text] [Related]
5. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.
Børresen AL; Hovig E; Smith-Sørensen B; Malkin D; Lystad S; Andersen TI; Nesland JM; Isselbacher KJ; Friend SH
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8405-9. PubMed ID: 1924299
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
8. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
Smith-Sørensen B; Gebhardt MC; Kloen P; McIntyre J; Aguilar F; Cerutti P; Børresen AL
Hum Mutat; 1993; 2(4):274-85. PubMed ID: 8401536
[TBL] [Abstract][Full Text] [Related]
9. Three germline mutations in the TP53 gene.
Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
[TBL] [Abstract][Full Text] [Related]
10. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis.
Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
Methods Mol Biol; 2005; 291():207-16. PubMed ID: 15502225
[TBL] [Abstract][Full Text] [Related]
11. Recurrent TP53 missense mutation in cancer patients of Arab descent.
Zick A; Kadouri L; Cohen S; Frohlinger M; Hamburger T; Zvi N; Plaser M; Avital E; Breuier S; Elian F; Salah A; Goldberg Y; Peretz T
Fam Cancer; 2017 Apr; 16(2):295-301. PubMed ID: 27866339
[TBL] [Abstract][Full Text] [Related]
12. Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France.
Preudhomme C; Fenaux P; Peyrat JP; Fournier J; Bonneterre J; Vennin P
Eur J Cancer; 1993; 29A(10):1476-8. PubMed ID: 8398277
[TBL] [Abstract][Full Text] [Related]
13. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
14. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips KA; Nichol K; Ozcelik H; Knight J; Done SJ; Goodwin PJ; Andrulis IL
J Natl Cancer Inst; 1999 Mar; 91(5):469-73. PubMed ID: 10070948
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
16. Screening for germline mutations of the p53 gene in familial breast cancer patients.
Patel UA; Perry M; Crane-Robinson C
Eur J Clin Invest; 1995 Feb; 25(2):132-7. PubMed ID: 7737263
[TBL] [Abstract][Full Text] [Related]
17. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
18. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
19. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
20. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
Martin AM; Kanetsky PA; Amirimani B; Colligon TA; Athanasiadis G; Shih HA; Gerrero MR; Calzone K; Rebbeck TR; Weber BL
J Med Genet; 2003 Apr; 40(4):e34. PubMed ID: 12676907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
